Research programme: immune modulation therapies - Aus Bio

Drug Profile

Research programme: immune modulation therapies - Aus Bio

Alternative Names: MD 2001; PC 2000

Latest Information Update: 16 Feb 2011

Price : $50

At a glance

  • Originator Aus Bio Limited
  • Class
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Crohn's disease; Hepatitis B; Hepatitis C; Respiration disorders; Ulcerative colitis

Most Recent Events

  • 16 Feb 2011 Preclinical development is ongoing in Australia
  • 19 Apr 2010 Preclinical development is ongoing in Australia
  • 17 Jan 2007 Preclinical trials in Hepatitis C in Australia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top